Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Michelis Fotios V) > Patient age and don...

Garcia‐Horton, AlejandroHans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, University of Toronto Toronto Ontario Canada;Department of Oncology, Juravinski Cancer Centre, Hamilton Health Sciences McMaster University Hamilton Ontario Canada (författare)

Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups

Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

2022-09-10
England :John Wiley & Sons,2022
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:uu-490700
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-490700URI
https://doi.org/10.1111/ejh.13850DOI
http://kipublications.ki.se/Default.aspx?queryparsed=id:150639257URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Background: Mixed results surround the accuracy of commonly used prognostic risk scores to predict overall survival (OS) and non-relapse mortality (NRM) in allogeneic hematopoietic stem cell transplant (allo-HCT) recipients. We hypothesize that a simple prognostic score performs better than conventional scoring systems.Patients and methods: OS risk factors, HCT-CI, age-HCT-CI, and augmented-HCT-CI were studied in 299 patients who underwent allo-HCT for myeloid and lymphoid malignancies. A scoring system was developed based on results and validated in a different cohort of 455 patients.Results: Two-year OS was 51% (95% confidence interval (CI) 0.45–0.56); 2-year NRM was 34% (95% CI 0.29–0.39). HCT-CI and associated scores were grouped into 0–2 and ≥3. Age and HLA mismatch status were the only risk factors to affect OS in multivariate analysis (p = 0.02 and 0.05, respectively). HCT-CI and associated scores were not informative for OS prediction. The weighted scoring system assigned 0 to 2 points for age < 50, 50–64, or ≥65, respectively, and 0–1 points for no HLA mismatch versus any mismatch (except HLA-DQ). Distinct 2-year OS (62%, 53%, and 38% [p = <0.001]) and NRM (24%, 34%, and 43% [p = 0.02]) groups were characterized. The scoring system was validated in a second independent cohort with similar results on OS and NRM (p < 0.001).Conclusions: A simple scoring system based on recipient's age and mismatch status accurately predict OS and NRM in two distinct cohorts of allo-HCT patients. Its simplicity makes it a helpful tool to aid clinicians and patients in clinical decision-making.

Ämnesord och genrebeteckningar

MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Hematologi hsv//swe
MEDICAL AND HEALTH SCIENCES Clinical Medicine Hematology hsv//eng
Immunologi
Immunology

Biuppslag (personer, institutioner, konferenser, titlar ...)

Cyriac, Sunu L.Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, University of Toronto Toronto Ontario Canada;Department of Medical Oncology and Hematology Amala Institute of Medical Sciences Thrissur India (författare)
Gedde‐Dahl, TobiasStem Cell Transplant Unit, Department of Hematology Oslo University Hospital, Institute of Clinical Medicine, University of Oslo Oslo Norway (författare)
Floisand, YngvarStem Cell Transplantation and Cellular Therapies Programme The Clatterbridge Cancer Centre NHS Foundation Trust Liverpool UK;CanCell – Centre of Cancer Cell Reprogramming University of Oslo Oslo Norway (författare)
Remberger, Mats,Professor,1955-Uppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)matre804 (författare)
Mattsson, JonasKarolinska Institutet,Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, University of Toronto Toronto Ontario Canada;Gloria and Seymour Epstein Chair in Cell Therapy and Transplantation, Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, University of Toronto Toronto Ontario Canada (författare)
Michelis, Fotios V.Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, University of Toronto Toronto Ontario Canada (författare)
Hans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, University of Toronto Toronto Ontario Canada;Department of Oncology, Juravinski Cancer Centre, Hamilton Health Sciences McMaster University Hamilton Ontario CanadaHans Messner Allogeneic Transplant Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre University Health Network, University of Toronto Toronto Ontario Canada;Department of Medical Oncology and Hematology Amala Institute of Medical Sciences Thrissur India (creator_code:org_t)

Sammanhörande titlar

Ingår i:European Journal of HaematologyEngland : John Wiley & Sons109:6, s. 672-6790902-44411600-0609

Internetlänk

Hitta via bibliotek

European Journal of Haematology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Garcia‐Horton, A ...; Cyriac, Sunu L.; Gedde‐Dahl, Tobi ...; Floisand, Yngvar; Remberger, Mats, ...; Mattsson, Jonas; visa fler...; Michelis, Fotios ...; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Hematologi

Artiklar i publikationen: European Journal ...

Av lärosätet: Uppsala universitet; Karolinska Institutet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se